China’s biotech stocks rebound hard after four years of slump, turning into Asia’s top performers this year. Funds are betting on more upside, signaling confidence in the sector’s comeback.
The surge comes amid a wider recovery in tech investments and easing regulatory pressures in China. Investors see value after years of caution.
This revival puts Chinese biotechnology firms back on the radar amid the global race for health tech innovation.
